Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 36Active not recruiting 10Unknown 6Terminated 6Recruiting 6Withdrawn 4Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Sarcoma 6

Conditions

Breast Neoplasms 412Carcinoma, Non-Small-Cell Lung 285Prostatic Neoplasms 208Neoplasms 202Neoplasm Metastasis 179Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 157Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 104Carcinoma, Renal Cell 104Brain Neoplasms 89Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 84Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 59

Interventions

plitidepsin 1atezolizumab 1TTI-621 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Liposarcoma × Clear all
NCT05496569 2025-11-21

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
26 enrolled
Sarcoma

Liposarcoma

NCT05580588 2025-06-13

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Shanghai Pharma Biotherapeutics USA Inc.

Phase 2 Terminated
14 enrolled 8 charts
Sarcoma

Liposarcoma

NCT04996004 2024-12-11

TTI-621-03

Pfizer

Phase 2 Terminated
76 enrolled 53 charts
Sarcoma

Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma

NCT05116683 2023-12-06

ATX-101

Columbia University

Phase 2 Terminated
4 enrolled 12 charts
Sarcoma

Leiomyosarcoma, Liposarcoma

NCT01876043 2021-01-25

APLIPO

Institut Bergonié

Phase 2 Terminated
24 enrolled 10 charts
Sarcoma

Liposarcoma, Neoplasm Metastasis, Recurrence

NCT02609984 2020-07-07

IMDZ-C232

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
89 enrolled 24 charts
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡